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Atrial fibrillation is a common arrhythmia; in fact, it may be 
the most common arrhythmia requiring antiarrhythmic drug 
therapy now that asymptomatic ventricular premature beats 
are thought to be inappropriate targets. Atria1 fibrillation can 
cause unpleasant palpitation, as well as decreased cardiac 
output due to loss of atria1 contribution to ventricular filling 
or inappropriate ventricular rates (1). In addition, this ar- 
rhythmia is associated with increased risk of stroke due to 
cerebral embolism (2). Atria1 fibrillation that does not termi- 
nate spontaneously usually can be converted by direct 
current countershock; unfortunately, the rate of recurrence 
is high (3,4). 
Role of class IA agents. Quinidine has been the mainstay 
of therapeutic attempts to prevent recurrence of atria1 fibril- 
lation. However, this therapy is far from ideal. It is fre- 
quently ineffective; in most trials only 20% to 50% of 
patients treated with quinidine (compared with 10% to 25% 
of patients given placebo) have remained in sinus rhythm for 
1 year after electrical conversion of atria1 fibrillation (5,6). 
Quinidine tends to decrease atrioventricular (AV) node 
refractoriness and thus to increase the ventricular rate 
during atria1 fibrillation. In addition, it frequently causes side 
effects and, occasionally, serious proarrhythmia. Other class 
IA agents, procainamide or disopyramide, add little in terms 
of efficacy or tolerance (7). Thus, atria1 fibrillation may be 
not only the most frequently treated arrhythmia, but also the 
most frustrating arrhythmia to treat. 
Newer drugs for atria1 fibrillation. In recent years a 
number of new antiarrhythmic agents have been introduced 
that may be useful in treating atria1 fibrillation. Several of 
these agents, flecainide, encainide and propafenone, are 
placed in class IC, and their action in atria1 muscle is 
primarily to slow conduction. These agents appear to have 
efficacy in preventing the recurrence of atria1 fibrillation, 
even in patients who have been refractory to quinidine, and 
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they tend to increase rather than decrease AV node refrac- 
toriness (8-12). They also are well tolerated. However, they 
tend to depress myocardial function and, inevitably, are 
associated with occasional serious proarrhythmia. Prelimi- 
nary findings from the Cardiac Arrhythmia Suppression Trial 
(CAST) (13) suggest that with flecainide or encainide proar- 
rhythmia frequently occurs late, long after any reasonable 
period of inpatient electrocardiographic monitoring. Flecain- 
ide-induced proarrhythmia, although common in cases of 
severe heart disease, was previously thought to be rare in 
relatively healthy hearts (14). However, one recent report 
(15) has raised questions regarding this premise. 
Two newer agents, amiodarone and sotalol, are placed in 
class III, and in atria1 muscle they primarily increase refrac- 
toriness. Both of these agents also have beta-adrenergic 
blocking activity. Amiodarone appears to be quite effective 
in preventing the recurrence of atria1 fibrillation and also 
increases AV node refractoriness (16-18). However, this 
agent is associated with considerable long-term toxicity. 
Furthermore, it has a very long half-life, making it difficult to 
substitute another drug in the event of failure. Although 
sotalol has properties that seem ideal for treatment of atria1 
fibrillation, there are few reported data on its use (19). 
Sequential trials of propafenone and sotalol: the present 
study. In this issue of the Journal, Antman et al. (20) report 
on their experience with sequential trials of propafenone and 
sotalol in a series of 109 patients with recurrent, symptom- 
atic atria1 fibrillation that had been unsuccessfully treated 
with one or more class IA agents. During treatment with 
propafenone, approximately 39% of the patients were free of 
recurrence for 6 months. Most of the remaining patients, in 
whom propafenone was either ineffective or poorly toler- 
ated, were subsequently treated with sotalol. It is striking 
that during loading with sotalol, 7 of 26 patients with chronic 
atria1 fibrillation had spontaneous conversion to sinus 
rhythm and that, during maintenance therapy with this drug, 
approximately 50% of patients were free of recurrence for 6 
months. Overall, 55% of the 109 patients were considered to 
have been successfully treated with one drug or the other. 
The study confirms that propafenone has efficacy in atria1 
fibrillation and it provides exciting new data regarding the 
usefulness of sotalol in patients with this arrhythmia. It 
implies that with addition of the newer agents, drug- 
refractory atria1 fibrillation may become a rare phenomenon. 
Several features of the present study (20) may have 
caused estimates of eficacy to be inflated. First, pro- 
pafenone and sotalol were frequently given multiple oppor- 
tunities to prevent atria1 fibrillation; often, when arrhythmia 
recurred during administration of one of the drugs, the 
dosage was increased and the trial restarted. In contrast, 
previous trials of class IA agents appear to have been 
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cursory. Second, the duration of follow-up was limited. 
Short follow-up is particularly problematic in evaluation of 
drug efficacy after electrical conversion of chronic atria1 
fibrillation (3,4). Finally, as the authors (20) point out, some 
recurrences of atria1 fibrillation may not have produced 
symptoms and thus may have gone undocumented. How- 
ever, even asymptomatic recurrence might cause cerebral 
emboli or insidious cardiac decompensation. Thus, although 
the results of the present study are encouraging, they prob- 
ably approximate a “best case” analysis. 
Current therapy of atrial fibrillation. It is clear that 
several of the newer antiarrhythmic agents have efficacy in 
preventing recurrence of atria1 fibrillation. Given the short- 
comings of quinidine, it is reasonable to ask whether any of 
these agents should replace quinidine as the first-line ther- 
apy. Caution is in order in this regard. There are few data to 
suggest that any of the new agents (except perhaps amio- 
darone) are more effective than quinidine (9,lO). Occasional 
efficacy in patients who have not responded to quinidine is 
consistent with the premise that different patients respond to 
different drugs, or it may simply reflect random variability of 
frequency of arrhythmia recurrence or selective reporting of 
favorable results. Ultimately, randomized clinical trials will 
be needed to determine the relative effectiveness, and 
safety, of the various agents. 
In the meantime, how should one treat atrialjbrillation? 
In patients with severe underlying heart disease it seems 
wise to start (and perhaps stop) with quinidine or procaina- 
mide. In these patients the risk of proarrhythmia, particu- 
larly late proarrhythmia, with class IC agents may be pro- 
hibitive (13). Furthermore, class IC agents or sotalol can 
aggravate heart failure. These concerns are less relevant in 
patients with little or no heart disease (14). In these patients 
class IA agents, class IC agents and, if available, sotalol 
seem to be reasonable alternatives. Agents from different 
classes can be used in sequential trials, in any order. 
However, because of its toxicity and long half-life, amio- 
darone should generally be used last, and only in patients 
with severe symptoms or those at exceptional risk for 
cerebral embolism. In any case, the present list of therapeu- 
tic options is a refreshing sight after so many years of meager 
offerings. 
References 
1. Lipkin DP, Frenneaux M, Stewart R, Joshi J, Lowe T, McKenna WJ. 
Delayed improvement in exercise capacity after cardioversion of atria1 
fibrillation to sinus rhythm. Br Heart J 1988:59:572-7. 
2. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assess- 
ment of chronic atrial fibrillation and risk of stroke: the Framingham 
Study. Neurology 1978;28:973-7. 
3. Morris JJ, Peter RH, McIntosh HD. Electrical conversion of atrial 
fibrillation: immediate and long-term results and selection of patients. 
Ann Intern Med 1%6;65:216-31. 
4. Waris E. Kreus K-E, Salokannel J. Factors influencing persistence of 
sinus rhythm after DC shock treatment of atrial fibrillation. Acta Med 
Stand 1971;189:161-6. 
5. Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein 0. Quinidine in 
maintenance of sinus rhythm after electroconversion of chronic atria1 
fibrillation: a controlled clinical study. Br Heart J 1971;33:518-21. 
6. Sodermark T. Jonsson B, Olsson A, et al. Effect of quinidine on 
maintaining sinus rhythm after conversion of atria1 fibrillation or flutter: a 
multicentre study from Stockholm. Br Heart J 1975;37:486-92. 
7. Szekely P, Sideris DA, Batson GA. Maintenance of sinus rhythm after 
atrial defibrillation. Br Heart J 1970:32:741-6. 
8. Berns E, Rinkenberger RL, Jeang MK, et al. Efficacy and safety of 
flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 
1987:59:1337-41. 
9. van Wijk LM, den Heijer P, Crijns HJ, van Gilst WH, Lie KI. Flecainide 
versus quinidine in the prevention of paroxysms of atrial fibrillation. 
J Cardiovasc Pharmacol 1989:13:32-6. 
10. Makynen PJ, Koskinen PJ, Saaristo TE, Liisanantti RK. Comparison of 
encainide and quinidine for supraventricular tachyarrhythmias. Am J 
Cardiol 1988:62:55L-9L. 
11. Porterheld JG, Porterfield LM. Therapeutic efficacy and safety of oral 
propafenone for atrial fibrillation. Am J Cardiol 1989;63: 114-6. 
12. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent 
paroxysmal atria1 fibrillation. Am J Cardiol 1989;63:817-9. 
13. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Prelim- 
inary report: effect of encainide and flecainide on mortality in a random- 
ized trial of arrhythmia suppression after myocardial infarction. N Engl J 
Med 1989:321:406-12. 
14. Morganroth J. Anderson JL, Gentzkow GD. Classification by type of 
ventricular arrhythmia predicts frequency of adverse cardiac events from 
flecainide. J Am Coll Cardiol 1986;8:607-15. 
15. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in 
patients treated for atria1 fibrillation. Ann Intern Med 1989;ll I: 107-I I, 
16. Horowitz LN, Spielman SR, Greenspan AM. et al. Use of amiodarone in 
the treatment of persistent and paroxysmal atrial fibrillation resistant to 
quinidine therapy. J Am Co11 Cardiol 1985:6:1402-7. 
17. Gold RL. Haffajee CI, Charos G, Sloan K, Baker S, Alpert J. Amiodarone 
for refractory atrial fibrillation. Am J Cardiol 1986;57:124-7. 
18. Brodsky MA, Alien BJ, Walker CJ, Casey TP, Luckett CR, Henry WL. 
Amiodarone for maintenance of sinus rhythm after conversion of atrial 
fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60: 
572-5, 
19. Singh BN. Nademanee K. Sotalol: a beta blocker with unique antiarrhyth- 
mic properties. Am Heart J 1987;114: 121-39. 
20. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. 
Therapy of refractory symptomatic atrial fibrillation and atria1 flutter: a 
staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 
1990:15:698-707. 
